Navigation Links
Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
Date:12/8/2011

SAN DIEGO, Dec. 8, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011, at 10:15 a.m. Eastern Time (7:15 a.m. Pacific Time) at the Waldorf=Astoria in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate is intended for weight management.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication of Arena's most advanced drug candidate and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the complete response letter for the lorcaserin new drug application or submission of a marketing authorization application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena Pharmaceuticals, Inc.Robert E. Hoffman, Vice President, Finance and Chief Financial Officer

858.453.7200 Investor Contact: Russo Partners, LLC

Media Contact: Russo Partners, LLCCindy McGee, Vice President

David Schull, President cindy.mcgee@russopartnersllc.com

david.schull@russopartnersllc.com619.213.6995

858.717.2310 

 

 


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
2. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
3. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
5. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
6. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
7. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
9. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
10. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
11. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company ... Novartis Pharma AG to distribute NuvoAir,s spirometry technology to physicians ... spirometry platform and Novartis, commitment to address the unmet medical ... ... "We ...
(Date:9/6/2017)... , Sept. 6, 2017  Medical ... knowledge and skills while treating their patients. ... hands-on experience without involving patients. Simulation provides ... Clinicians can carry out procedures, refine techniques ... risk. Integration of new technology, such as ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and ... DoseCheck solution. Scannerside DoseCheck is a third-party Vendor neutral ... CT scanners and allows compliance with current MITA standards. ... proprietary XR 29 DoseCheck solution is specifically designed to ... alerts of potential radiation doses over a predefined threshold. ...
Breaking Medicine Technology:
(Date:9/21/2017)... , ... September 21, 2017 , ... ... their communities, nine governmental public health departments have been awarded five-year accreditation status ... mean that the benefits of being served by a PHAB-accredited health department ...
(Date:9/21/2017)... ... September 21, 2017 , ... In addition to sticking with ... more holistic approach and use natural alternatives for all house cleaning products, disinfectants, ... USDA guaranteeing that, the new line of essential oils, are all 100% organic ...
(Date:9/21/2017)... ... , ... The New England Center for Children® (NECC®), a global leader in ... to the Board of Directors. , “The New England Center for Children is ... invaluable addition to our team,” said Vincent Strully, Jr., President and CEO of The ...
(Date:9/21/2017)... York, New York (PRWEB) , ... September 21, 2017 , ... ... exhibition, named “One Yoga Mat Revolution” on 6th, 7th and 8th October at Miranda ... couple’s renowned yoga mat art pieces, such as Zen Kodo mat. Wanderlust , ...
(Date:9/21/2017)... ... ... FlipBelt, the fitness brand that specializes in problem solving fitness accessories, has brought their ... of their FlipBelt Crops. , The new fitness bottoms feature an integrated FlipBelt fitness ... gym, on the trail, or on-the-go. , “We always thought the FlipBelt could be ...
Breaking Medicine News(10 mins):